Team:KU Leuven/Project/Glucosemodel/EBF

In this part, we will give some more information about the E-β-farnesene (EBF) part of the project. EBF is an alarm pheromone, released by almost all of the 4000 aphid species known thus far in response to the presence of predators (e.g. the ladybug) or other disturbances. In response to the produced EBF, aphids change their metabolism and turn into a winged form, allowing them to "flee the scene" and thus increase their survival rate. Apart from the short term repelling effect, EBF can also cause long term effects: changes in aphid’s development, fecundity, survival when introduced to different growth stages, etc. Moreover, natural aphid predators such as the ladybugs are attracted by EBF.
Hence, having our BanAphids produce EBF should help to repel aphids from our plant of choice. In the following sections, we will give you a general background of EBF synthase followed by an overview of the model and the genes, the wetlab work and the biobricks we built for the EBF part. Finally we have made some suggestion how to optimise the production of EBF in the future. For this we will take you on a tour through the pathways that result in EBF and the problems that arise with this. Of course we have added possible solutions to these problems.

We cloned and expressed the EBF synthase gene in E. coli. This enzyme will break down (2E,6E)-farnesyl diphosphate into (E)-β-farnesene (EBF) and diphosphate (see reaction scheme below).
The enzyme prefers bivalent cations as cofactors; a Mg²⁺ concentration of 5 mM should be beneficial for EBF synthase function. The ideal pH for EBF synthase will be between 5.5 and 7.

The EBF construct we designed consists of a constitutive promoter with a lac operator, the EBF synthase itself and a double terminator.We used BBa_B0015 for the double terminator. EBF is not only made by aphids but also by plants and other organisms in a form of bio-mimicry. We obtained two different sources of the EBF gene. One gene originates from the soil bacterium Streptomyces coelicolor (Centre of Microbial and Plant Genetics of KU Leuven). We chose this plant-residing bacterium because it would be a perfect chassis for the ultimate expression of EBF in our E. coligy system. The other EBF gene is from the plant Artemisia annua (sweet wormwood) and was a kind gift from Professor Peter Brodelius (Kalmar University, Sweden). Here we were inspired with the plant origin. The K_M for the Artemisia annua protein is calculated at 0.0021 mM, with a Kcat/K_M=4.5 and a turnover number of 0.0095 s^-1. For the Streptomyces coelicolor protein the K_M is 0.0168 mM and the turnover number 0.019 s^-1.
Unfortunately, the EBF synthase from Streptomyces coelicolor is a bifunctional enzyme, not only processing β-farnesene but also containing albaflavenone synthase activity. For this reason, we chose to follow up on the Artemisia annua gene and product. For our construct, our first choice was a medium strength promoter with medium RBS (BBa_K608006); we nonetheless also made the construct with a strong promoter and RBS. The lac operator in front of the EBF synthase gene will allow us to switch on/off the transcription of EBF synthase gene.

Gettin' the gene

In the case of EBF synthase gene from Streptomyces coelicolor, we amplified this gene with a colony PCR. The EBF synthase gene from Artemisia annua was received in the pET28 vector from professor Brodelius (Kalmar University, Sweden). In this gene an additional EcoRI restriction site is present, which will conflict with the standard iGEM cloning work. Therefore we removed this site via site directed mutagenesis after transferring the gene into the iGEM pSB1C3 backbone.

Cutting and pasting

Once we obtained the target gene (EBF) in the standard pSB1C3 backbone, we started our cloning work. We used a pSB1C3 with a promoter or terminator as chassis, cut this open and inserted the gene of interest. When ligating the insert in front of the double terminator, we cut the vector with EcoRI and XbaI, and the insert with EcoRI and SpeI. The promotor vector on the other hand is cut with SpeI and PstI restriction sites, and the insert is cut with XbaI and PstI restriction sites. This works because SpeI and XbaI are isoschizomers.
Ligations were performed in parallel in two different ways. In one setup we ligated for 20 minutes at 16 ℃, and in comparison, the second ligation of the same products was conducted at 16 ℃ overnight.
For transformation, we used both chemically competent cells and electrocompetent cells. Electroporation had a higher efficiency when compared to heat shock transformation.

Confirmation

After we observed colonies the next day, we needed to confirm the products. The first step we did was usually a colony PCR to check if the insert was in the vector, this was followed up by digestion confirmation after the plasmid extraction. Only the plasmids which succeeded in both controls were send for sequencing, the final confirmation.

gBlocks

Meanwhile, we also built the EBF construct with a lac operator between the promoter and gene, using the gBlock principle. We designed the gBlocks, assembled them and ligated the insert into pSB1C3 backbone. The colonies obtained also went through the three confirmation steps mentioned above before we were satisfied.

For more details of the labwork and the wetlab difficulties as well as how we overcame them, please consult our wetlab journal.

After we overcame a lot of difficulties, we finally made the following bricks at the end of the summer.

FPP is an important precursor, used for the biosynthesis of lots and lots of compounds. Once we insert a plasmid containing the β-farnesene synthase gene, we may obtain only a very small amount of β-farnesene, since the precursor amount wasn't increased and there simply isn’t enough FPP available to produce the amount of β-farnesene to fully use the capacity of the EBF synthase enzyme we brought in.
A solution may be to co-transform plasmids to engineer a mevalonate pathway in E. coli, thereby upregulating the production of FPP. This larger amount of FPP may then be converted to β-farnesene, creating a large enough amount of this volatile. This was demonstrated many times by J.D. Keasling in S. cerervisiae, while Martin et al., (2003) implemented this mevalonate pathway in E. coli. In the article, they described their successful efforts to create a high level production of amorphadiene by introducing the mevalonate pathway in E. coli. However, expression of this heterologous pathway led to such an abundance of isoprenoid precursors that cells ceased to grow or mutated to overcome the toxicity. This once again shows the need for a controlled production of the elements in this pathway; too much is equally detrimental as too little.

Even though we do not need a very high production of EBF it would be definitely better to optimise the pathway, by using the plasmids pMevT and pMBIS, described above. Implementing them into our BanAphids along with the synthetic β-farnesene synthase gene could result into high yields of β-farnesene. This way the amount of EBF can be easily changed via the amount of bacteria used or the concentration of the cofactor Mg²⁺.
Due to the short amount of time iGEM offered we did not yet started doing this, but this is definitely something future teams might look into.

Kajiwara S., Fraser P., Kondo K., Misawa N., Expression of an exogenous isopentenyl diphosphate isomerase gene enhances isoprenoid synthesis in Escherichia coli, Biochem J. 324, 421-426 (1997).
Martin V., Pitera D., Withers S., Newman J., Keasling J., Engineering a mevalonate pathway in Escherichia coli for production of terpenoids, Nature Biotechnology 21(7), 796-802 (2003).